# Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia

> **NCT07680946** · PHASE2 · RECRUITING · sponsor: **TG Therapeutics, Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Ublituximab

## Key facts

- **NCT ID:** NCT07680946
- **Lead sponsor:** TG Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-27
- **Primary completion:** 2028-12-12
- **Final completion:** 2029-03-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07680946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07680946, "Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07680946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*